Presentation on the benefits of EnteraGam® (serum-derived bovine immunoglobulin/protein isolate, SBI) in patients with pouchitis to occur at the 2015 Advances in Inflammatory Bowel Diseases (AIBD) Annual Meeting
Entera Health, Inc. today announced an upcoming presentation of results from a retrospective chart review of patients with pouchitis who were placed on SBI therapy because they were refractory to other treatment options. Nutritional therapy with SBI helped patients achieve clinical, asymptomatic remission of their pouchitis in 9 out of 10 cases that were reviewed. The presentation will be given by Dr. Larry Good (State University of New York at Stony Brook & South Nassau Communities Hospital, Oceanside, NY) at the 2015 AIBD Annual Meeting in Orlando, FL, on December 10-12, 2015. Dr. Good will be available to discuss the presentation during the poster viewing and reception at the times listed below.
To learn more, please visit Entera Health at Booth #32.
Remission of Pouchitis in Patients Following Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI) Therapy. Larry Good, MD, Assistant Professor of Medicine, State University of New York at Stony Brook & South Nassau Communities Hospital, Oceanside, NY USA
Poster ID: #P-003
Friday, December 11, 2015
10:00-10:30 Poster Viewing
3:45-4:00 Poster Viewing
6:00-7:00 Poster Reception
Saturday, December 12, 2015
10:00-10:30 Poster Viewing
EnteraGam® is a prescription medical food product intended to provide for distinctive nutritional requirements that are unique for the clinical dietary management of specific intestinal disorders [e.g., in irritable bowel syndrome with diarrhea (IBS-D), inflammatory bowel disease (IBD), and HIV-associated enteropathy]. EnteraGam® is required to be used under physician supervision as part of ongoing medical care for a specific condition or disease. EnteraGam® is also indicated for the clinical dietary management of enteropathy in patients who, because of therapeutic or chronic medical needs, have limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients. For full prescribing information, please visit the product website at http://enteragam.com/.
Important Safety Information
EnteraGam® is a specially formulated protein source for the management of intestinal disorders. The product has been extremely well tolerated for up to a year in HIV patients and up to 8 months in infants. The major side effects in clinical trials (2-5%) have included mild nausea, constipation, stomach cramps, headache, and increased urination. EnteraGam® is contraindicated for patients with a hypersensitivity (allergy) to beef, or any components in EnteraGam®. Therefore, patients who have an allergy to beef or any component of EnteraGam® should not take this product. EnteraGam® has not been studied in pregnant or nursing women. The choice to administer EnteraGam® for patients who are pregnant or nursing is at the clinical discretion of the prescribing physician. Medical foods like EnteraGam® are required by FDA regulations to be dosed and monitored by physicians as part of ongoing care for patients with chronic conditions or diseases.
About Entera Health, Inc.
Entera Health, Inc. is focused on improving worldwide health through the development of clinically safe biotherapeutics to address unmet needs. The staff's passion is to help people thrive through healthier living. The staff's motivation for conducting basic research, clinical studies, and appropriately educating patients and healthcare providers is driven to meet this goal. Learn more at http://www.enterahealth.com/.
For questions, please contact:
Aage Lauridsen, Chief Executive Officer